Daniel C Sharp

US Patent:

20110176996, Jul 21, 2011

Filed:

Dec 30, 2010

Appl. No.:

12/982250

Inventors:

Kim Leslie O'Neill - Provo UT, US
Robert Alan Whitehurst - Buena Vista VA, US
Jaden Duss Evans - Centerville UT, US
Daniel Williar Sharp - Buckeye AZ, US
Melissa Marie Alegre - Saginaw TX, US

Assignee:

Brigham Young University - Provo UT

International Classification:

A61K 39/395
G01N 33/573
C07K 16/40
C07K 14/00
C07H 21/04
A61P 35/02
A61K 49/00
A61P 35/00
A61K 49/16
A61K 49/04
A61K 51/10

US Classification:

424 149, 435 74, 4241381, 4241331, 4241781, 5303877, 530324, 536 235, 424 96, 5303873, 424 934, 424 94

Abstract:

Compositions and methods are provided for the diagnosis, treatment, and medical management of cancers. The methods include the use of antibodies and other binding molecules that specifically bind to one or more nucleotide salvage pathway enzymes (SPEs) selected from the group consisting of adenine phosphoribosyltransferase (APRT), hypoxanthine-guanine phosphoribosyltransferase (HGPRT), deoxycytidine kinase (dCK); and thymidine kinase 1 (TK1) and complexes comprising SPEs, for detection of the SPE(s) on or in cancer cells and/or on or in body fluids and tissues of cancer patients. Binding of SPEs is useful in the methods provided herein for diagnosing cancer, determining prognosis of cancer and assessing the effectiveness of cancer treatments. Immunoassay systems for use in the methods are also provided, including sandwich immunoassays. In addition, an amino acid sequence comprising a novel TK1 binding site is provided, as well as nucleotide sequences encoding it.